Fundraising FoxDicerna Pharmaceuticals
5 known investors
Find your way into Dicerna Pharmaceuticals
Sign up to find every way you can get introduced to Dicerna Pharmaceuticals
- Your email: who you already know at Dicerna Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Dicerna Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally. The company conducts research and development, collaborates with scientists and biotech innovators, and has reached millions of patients through its innovative therapeutic approaches.
Investors · 5
How we know: Access Biotechnology's portfolio page · Not right? Tell us
How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $184.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Dicerna Pharmaceuticals do?
- A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally. The company conducts research and development, collaborates with scientists and biotech innovators, and has reached millions of patients through its innovative therapeutic approaches.
- Who are Dicerna Pharmaceuticals's investors?
- Dicerna Pharmaceuticals's investors include Access Biotechnology, Bain Capital Life Sciences, Ridgeback Capital, Oxford Bioscience Partners, RA Capital.